News
Lecanemab wins breakthrough therapy designation in Alzheimer’s disease
Biogen and Eisai announced yesterday that their investigational Alzheimer’s disease (AD) treatment lecanemab has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA).